EPZM Epizyme Inc.

16.95
-1.75  -9%
Previous Close 18.70
Open 18.60
Price To book 6.62
Market Cap 993365191
Shares 58,605,616
Volume 1,018,934
Short Ratio 14.71
Av. Daily Volume 582,315

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171086508
  2. 8-K - Current report 171084618
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171083319
  4. 8-K - Current report 171036974
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009957

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data at ASCO 2017 - June 4, 2017. Abstract 11057.
Tazemetostat
Solid tumors - cancer
Phase 2 dosing commenced August 2016. Enrollment completed June 2017 with data due 2018.
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 data released June 14, 2017 - DLBCL ORR 29%.
Tazemetostat
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma

Latest News

  1. Epizyme (EPZM) Looks Good: Stock Adds 7.8% in Session
  2. Epizyme Announces Closing of Public Offering of Common Stock
  3. Why Blue Apron Holdings, Tailored Brands, and Epizyme Jumped Today
  4. Is It Too Late To Buy Epizyme Inc (EPZM)?
  5. Epizyme Announces Pricing of Public Offering of Common Stock
  6. Epizyme Announces Proposed Public Offering of Common Stock
  7. Epizyme to Participate in Upcoming Investor Conferences
  8. Epizyme Announces Leadership Transition for Finance Organization
  9. Edited Transcript of EPZM earnings conference call or presentation 4-Aug-17 12:00pm GMT
  10. Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
  11. Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : August 7, 2017
  12. Epizyme reports 2Q loss
  13. Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring
  14. Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss
  15. Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
  16. Investor Network: Epizyme, Inc. to Host Earnings Call
  17. Featured Company News - US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
  18. What to Expect from Epizyme (EPZM) This Earnings Season?
  19. US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
  20. Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171086508
  2. 8-K - Current report 171084618
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171083319
  4. 8-K - Current report 171036974
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009957
  6. 8-K - Current report 171006855
  7. 8-K - Current report 17933667
  8. 8-K - Current report 17928832
  9. 8-K - Current report 17875642
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17820398